NCT03849261
Unknown
Phase 1
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults
Overview
- Phase
- Phase 1
- Intervention
- CKD-387
- Conditions
- Type2 Diabetes Mellitus
- Sponsor
- Chong Kun Dang Pharmaceutical
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- Cmax of Metformin
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of the clinical trail is to evaluate the pharmacokinetics and safety/tolerability after oral administration of CKD-387 and D635 in healthy adults.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy adults aged 19 to 55 years
- •Females must be menopause or surgical infertility
- •Signed informed consent form
- •Other inclusion criteria, as defined in the protocol
Exclusion Criteria
- •History of clinically significant hepatic, renal, nervous, immune, respiratory, endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder
- •Clinical laboratory test values are outside the accepted normal range at Screening
- •aspartate aminotransferase(AST), alanine aminotransferase(ALT) \> 1.25 times the upper limit of the normal range
- •Total Bilirubin \> 1.5 times the upper limit of the normal range
- •creatine phosphokinase(CPK) \> 1.5 times the upper limit of the normal range
- •estimated Glomerular Filtration Rate(eGFR, MDRD\* formula) \< 60 mL/min/1.73m2 (\*MDRD: Modification of Diet in Renal Disease)
- •Positive reaction on following tests: Hepatitis B, Hepatitis C, human immunodeficiency virus(HIV) and syphilis
- •systolic blood pressure(SBP) ≥ 150 mmHg or \< 90 mmHg, diastolic blood pressure(DBP) \> 100 mmHg or \< 50 mmHg
- •Subject who smoke heavily or drink caffeine or alcohol continuously and who cannot discontinue smoking, caffeine or alcohol intake during hospitalization
- •Participated in a clinical trial within 90 days prior to 1st IP dosing
Arms & Interventions
Group 1
* Period 1: D635 * Period 2: CKD-387
Intervention: CKD-387
Group 2
* Period 1: CKD-387 * Period 2: D635
Intervention: CKD-387
Group 1
* Period 1: D635 * Period 2: CKD-387
Intervention: D635
Group 2
* Period 1: CKD-387 * Period 2: D635
Intervention: D635
Outcomes
Primary Outcomes
Cmax of Metformin
Time Frame: 0 hour ~ 48 hour after drug administration
Maximum plasma concentration of Metformin
AUClast of Dapagliflozin
Time Frame: 0 hour ~ 48 hour after drug administration
Area under the plasma concentration-time curve to last concentration of Dapagliflozin
AUClast of Metformin
Time Frame: 0 hour ~ 48 hour after drug administration
Area under the plasma concentration-time curve to last concentration of Metformin
Cmax of Dapagliflozin
Time Frame: 0 hour ~ 48 hour after drug administration
Maximum plasma concentration of Dapagliflozin
Secondary Outcomes
- AUCinf of Dapagliflozin(0 hour ~ 48 hour after drug administration)
- AUCinf of Metformin(0 hour ~ 48 hour after drug administration)
- Tmax of Dapagliflozin(0 hour ~ 48 hour after drug administration)
- Tmax of Metformin(0 hour ~ 48 hour after drug administration)
- T1/2 of Dapagliflozin(0 hour ~ 48 hour after drug administration)
- T1/2 of Metformin(0 hour ~ 48 hour after drug administration)
- Vd/F of Dapagliflozin(0 hour ~ 48 hour after drug administration)
- Vd/F of Metformin(0 hour ~ 48 hour after drug administration)
- CL/F of Dapagliflozin(0 hour ~ 48 hour after drug administration)
- CL/F of Metformin(0 hour ~ 48 hour after drug administration)
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 1
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed ConditionType 2 Diabetes MellitusNCT03849339Chong Kun Dang Pharmaceutical20
Completed
Phase 1
The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed ConditionType 2 Diabetes MellitusNCT03738449Chong Kun Dang Pharmaceutical23
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy VolunteersEssential HypertensionType 2 DiabetesNCT06636877Boryung Pharmaceutical Co., Ltd52
Unknown
Phase 1
The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375Type 2 Diabetes MellitusNCT03848637Chong Kun Dang Pharmaceutical28
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"Type 2 Diabetes MellitusEssential HypertensionNCT06226727Boryung Pharmaceutical Co., Ltd52